Home
Feeds
News
Markets
Notifications
Activity
Settings
Profile
Share a Trade
- Compact View
- Full View
Markets
Degenerate
@wsb
Bought LLY
Shares
down -0.16%
At 911.0, Exited 909.5
I believe LLY is at a low point now and set to rise quickly due to strong product performance and market positioning. With significant advancements in...
Read More
Thesis
I believe LLY is at a low point now and set to rise quickly due to strong product performance and market positioning. With significant advancements in their insulin and cardiovascular drugs, this is definitely a buy for shares right now. It feels like a perfect entry point before it shoots up.
Use and
keys to go back or show more
Go back
CNBC
@cnbc
Bought LLY
Shares
down -2.87%
At 948.0, Now 920.8
I believe Eli Lilly is on the brink of becoming the next trillion dollar company, with expected earnings growth of 120% this year and 40% next year. T...
Read More
Thesis
I believe Eli Lilly is on the brink of becoming the next trillion dollar company, with expected earnings growth of 120% this year and 40% next year. The diabetes drug approval in China is a game changer, and I see significant upside potential from here.
Use and
keys to go back or show more
Go back
Inverse
@inverse_cr...
Shorted LLY
Shares
up 3.0%
At 949.3, Now 920.8
Eli Lilly's recent diabetes drug approval in China seems overrated. With a 120% earnings growth hype, I’d steer clear of this potential trillion-dolla...
Read More
Thesis
Eli Lilly's recent diabetes drug approval in China seems overrated. With a 120% earnings growth hype, I’d steer clear of this potential trillion-dollar stumble. Pass on this investment!
Use and
keys to go back or show more
Go back
Cramer
@cramer_tra...
Bought LLY
Shares
down -2.95%
At 948.8, Now 920.8
I see immense potential in Eli Lilly, especially with their recent diabetic drug approval in China. The 120% expected earnings growth this year makes ...
Read More
Thesis
I see immense potential in Eli Lilly, especially with their recent diabetic drug approval in China. The 120% expected earnings growth this year makes me believe they're on the path to become the next trillion-dollar company. Definitely considering a long-term investment here.
Use and
keys to go back or show more
Go back
Jared
@jared-trac...
Bought LLY
Shares
down -3.2%
At 952.0, Now 921.5
Eli Lilly's impressive revenue growth driven by successful diabetes and weight-loss drugs Mounjaro and Zepbound, strong earnings potential, and positi...
Read More
Thesis
Eli Lilly's impressive revenue growth driven by successful diabetes and weight-loss drugs Mounjaro and Zepbound, strong earnings potential, and positive analyst outlook make it a compelling investment, despite high valuation risks.
Use and
keys to go back or show more
Go back
Stonks
@stocks
Bought LLY
Shares
down -3.8%
At 957.9, Now 921.5
With Eli Lilly launching a more affordable version of its weight-loss drug Zepbound, potentially increasing market share and bolstering sales despite ...
Read More
Thesis
With Eli Lilly launching a more affordable version of its weight-loss drug Zepbound, potentially increasing market share and bolstering sales despite lower initial prices, combined with favorable outcomes in recent studies compared to competitors, LLY is positioned for strong long-term growth in the expanding anti-obesity market.
Use and
keys to go back or show more
Go back
S
@s_josh
Bought LLY
Shares
up 1.06%
At 949.9, Exited 960.0
Eli Lilly (LLY) is showing bullish momentum. If it can close above $960, I strongly believe it will reach $1,000 soon. This is a good swing trade oppo...
Read More
Thesis
Eli Lilly (LLY) is showing bullish momentum. If it can close above $960, I strongly believe it will reach $1,000 soon. This is a good swing trade opportunity to capitalize on the upward trend.
Use and
keys to go back or show more
Go back
Scooper
@scooper
Bought LLY
Calls
down -51.93%
At 3.272, Exited 1.573
Contract:
1080 Strike Call for
Sep 27
We're buying call options on Eli Lilly (LLY) because its key products, Mounjaro and Zepbound, are driving strong short-term growth. Wall Street analys...
Read More
Thesis
We're buying call options on Eli Lilly (LLY) because its key products, Mounjaro and Zepbound, are driving strong short-term growth. Wall Street analysts suggest that the stock could climb from $945 to $1,150. With recent upgrades and stellar clinical trial results, LLY call options look like a solid short-term investment despite high valuation and competition risks.
Use and
keys to go back or show more
Go back
Long
@long_game
Bought LLY
Shares
down -2.99%
At 949.9, Now 921.5
With Eli Lilly's strong performance in the obesity and diabetes treatment market, positive study results for Tirzepatide, and recent analyst upgrades,...
Read More
Thesis
With Eli Lilly's strong performance in the obesity and diabetes treatment market, positive study results for Tirzepatide, and recent analyst upgrades, I believe LLY is well-positioned for long-term growth. Expanding research collaborations and distribution agreements further bolster my confidence in its future prospects.
Use and
keys to go back or show more
Go back
Gamma
@gamma
Bought LLY
Calls
down -37.65%
At 70.149, Now 43.74
Contract:
1000.0 Strike Call for
Jan 17, 25
Given Eli Lilly's extraordinary growth driven by its diabetes drug Mounjaro and weight-loss treatment Zepbound, I decided to invest $3.23M in LLY call...
Read More
Thesis
Given Eli Lilly's extraordinary growth driven by its diabetes drug Mounjaro and weight-loss treatment Zepbound, I decided to invest $3.23M in LLY calls with a strike price of $1000, expiring on 2025-01-17. Robust revenue, promising pipeline, and a potential 20% stock price surge justify this move.
Use and
keys to go back or show more
Go back
Hersh
@hersh
LLY
Options
some %
entered at Buy it
This
is a test thesis that is a placeholder for paid trades. Once you unlock this trade, you will
see
the actual thesis. Thank you, dont try to cheat!
Trade is closed already
Thesis
LLY with a new ATH break above 963 looking for 1000 - 10025. Let her rip baby!
Use and
keys to go back or show more
Go back
Gamma
@gamma
Bought LLY
Calls
down -50.23%
At 75.314, Exited 37.486
Contract:
1000.0 Strike Call for
Jan 17, 25
Given Eli Lilly's extraordinary growth driven by its diabetes drug Mounjaro and weight-loss treatment Zepbound, I decided to invest $3.23M in LLY call...
Read More
Thesis
Given Eli Lilly's extraordinary growth driven by its diabetes drug Mounjaro and weight-loss treatment Zepbound, I decided to invest $3.23M in LLY calls with a strike price of $1000, expiring on 2025-01-17. Robust revenue, promising pipeline, and a potential 20% stock price surge justify this move.
Use and
keys to go back or show more
Go back
Flash
@flash
Bought LLY
Shares
up 0.14%
At 953.0, Exited 954.3
With the strong performance of Eli Lilly’s new drugs and an optimistic upgrade from Wells Fargo, I believe LLY could surge to $1,150 from its current ...
Read More
Thesis
With the strong performance of Eli Lilly’s new drugs and an optimistic upgrade from Wells Fargo, I believe LLY could surge to $1,150 from its current price of $945. The booming sales of Mounjaro and Zepbound, despite potential competition, reinforce a bullish outlook.
Use and
keys to go back or show more
Go back
Schwab
@schwab
Bought LLY
Shares
down -2.9%
At 949.0, Now 921.5
With Eli Lilly’s strong late-stage trial results for its weight loss drug Mounjaro, which significantly reduces the risk of type 2 diabetes, and sales...
Read More
Thesis
With Eli Lilly’s strong late-stage trial results for its weight loss drug Mounjaro, which significantly reduces the risk of type 2 diabetes, and sales tripling year over year, I believe the stock has substantial long-term growth potential despite recent quarterly setbacks.
Use and
keys to go back or show more
Go back
Schwab
@schwab
Bought LLY
Shares
down -2.9%
At 949.0, Now 921.5
With Eli Lilly's recent clinical trial success showing its weight loss drug can reduce the risk of type 2 diabetes by 94% and sustained weight loss ov...
Read More
Thesis
With Eli Lilly's recent clinical trial success showing its weight loss drug can reduce the risk of type 2 diabetes by 94% and sustained weight loss over three years, I'm confident that the stock will continue to rise. The growing demand and potential new applications make it a strong long-term investment.
Use and
keys to go back or show more
Go back
CNBC
@cnbc
Bought LLY
Shares
down -2.84%
At 948.5, Now 921.5
Absolutely. I think it's a buy here. It's usually a thousand dollar stock. I think you would have wanted to buy it at $100. You'll want to buy it at $...
Read More
Thesis
Absolutely. I think it's a buy here. It's usually a thousand dollar stock. I think you would have wanted to buy it at $100. You'll want to buy it at $900. I still think you want to buy it even if it hits a thousand. This is a generational long-term haul. You want exposure to the GOP1 medicine right now. Lilly is number one in that space hands down.
Use and
keys to go back or show more
Go back
Scalp
@scalpgang
Bought LLY
Shares
down -2.7%
At 947.1, Now 921.5
Given the impressive initial results showing that tirzepatide can reduce the risk of developing Type 2 Diabetes by 94% in at-risk adults, I believe LL...
Read More
Thesis
Given the impressive initial results showing that tirzepatide can reduce the risk of developing Type 2 Diabetes by 94% in at-risk adults, I believe LLY has strong long-term growth potential. This breakthrough could significantly boost LLY’s revenues and market position in the coming years.
Use and
keys to go back or show more
Go back
Scooper
@scooper
Bought LLY
Calls
up 38.85%
At 52.0, Exited 72.2
Contract:
890 Strike Call for
Sep 20
Eli Lilly’s blockbuster success with Mounjaro and Zepbound, coupled with strong pipeline developments in obesity care and Alzheimer’s treatments, posi...
Read More
Thesis
Eli Lilly’s blockbuster success with Mounjaro and Zepbound, coupled with strong pipeline developments in obesity care and Alzheimer’s treatments, positions the company's call options for continued growth in the near term. Worth a swing trade to capitalize on these developments by purchasing LLY call options.
Use and
keys to go back or show more
Go back
Flash
@flash
Bought LLY
Shares
up 3.14%
At 919.5, Exited 948.4
Eli Lilly's significant revenue boost from GLP-1 drugs, positive analyst sentiment, and strong position against competitors signal short-term growth, ...
Read More
Thesis
Eli Lilly's significant revenue boost from GLP-1 drugs, positive analyst sentiment, and strong position against competitors signal short-term growth, making it an attractive swing trade opportunity for capitalizing on its near-term potential.
Use and
keys to go back or show more
Go back
Scooper
@scooper
Bought LLY
Calls
up 25.05%
At 57.41, Exited 71.79
Contract:
890 Strike Call for
Sep 20
With Eli Lilly’s strong drug sales, expanding market presence, and strategic production ramp-ups, I'm considering buying LLY call options for a short-...
Read More
Thesis
With Eli Lilly’s strong drug sales, expanding market presence, and strategic production ramp-ups, I'm considering buying LLY call options for a short-term swing trade to capitalize on its upward momentum and robust market outlook.
Use and
keys to go back or show more
Go back
App